| Co-Investigator(Kenkyū-buntansha) |
問山 裕二 三重大学, 医学部附属病院, 准教授 (00422824)
井上 靖浩 三重大学, 医学系研究科, 客員准教授 (20324535)
毛利 靖彦 三重大学, 医学系研究科, 客員准教授 (70345974)
沖上 正人 三重大学, 医学系研究科, リサーチアソシエイト (90722596)
|
|---|
| Budget Amount *help |
¥15,470,000 (Direct Cost: ¥11,900,000、Indirect Cost: ¥3,570,000)
Fiscal Year 2018: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
Fiscal Year 2017: ¥910,000 (Direct Cost: ¥700,000、Indirect Cost: ¥210,000)
Fiscal Year 2016: ¥3,380,000 (Direct Cost: ¥2,600,000、Indirect Cost: ¥780,000)
Fiscal Year 2015: ¥2,990,000 (Direct Cost: ¥2,300,000、Indirect Cost: ¥690,000)
Fiscal Year 2014: ¥7,020,000 (Direct Cost: ¥5,400,000、Indirect Cost: ¥1,620,000)
|
|---|
| Outline of Final Research Achievements |
The aim of this study was to identify non-invasive diagnostic biomarker for colorectal cancer. Array-based comprehensive analysis demonstrated that miR-1290 was one of candidate for diagnostic marker in CRC patients, and we validated diagnostic potential of serum miR-1290 using serum specimens from patients with adenoma and CRC. Surprisingly, serum miR-1290 could identify patients with adenoma or CRC with high accuracy (AUC=0.83, 0.718, respectively).
|
